MY ACCOUNT | NEWSLETTER |

Pharmacokinetics of single dose oral pimobendan in the ferret


Therapeutic options and dosing recommendations for congestive heart failure in the domestic ferret are currently extrapolated from domestic dogs and cats. The goal of this study was to determine the pharmacokinetics of oral pimobendan in the domestic ferret.

Twelve domestic ferrets were administered a single dose (average 0.4 mg/kg) of pimobendan in a commercially available, chewable, meat-flavored tablet formulation. High-performance liquid chromatography and fluorescence detection were used to measure pimobendan and the metabolite O-desmethylpimobendan (ODMP) in plasma samples collected at 0, 0.25, 0.5, 1, 2, 4, 6, 9, and 12 hours after administration using a sparse sampling protocol.

Pharmacokinetic parameters for pimobendan and ODMP were as follows: peak plasma concentration, 14.29 ng/mL and 16.88 ng/mL; time to peak plasma concentration, 1.69 hours and 1.97 hours; area under the curve, 129.87 ng*h/mL and 190.97 ng*h/mL; and elimination half-life, 4.97 hours and 6.32 hours, respectively. No adverse events were noted.

A single dose of oral pimobendan in ferrets reached concentrations higher than that reported for dogs by the manufacturer and similar to peak plasma concentrations correlated with a therapeutic effect in healthy dogs in a separate study. Individual variability was high and plasma concentrations in at least half of the ferrets remained at or below the lower limit of quantification throughout the duration of the study. Additional studies are needed to characterize the pharmacodynamics, oral bioavailability, and duration of action to facilitate dosing recommendations for pimobendan in the domestic ferret.


“Population pharmacokinetics of single dose oral pimobendan in the ferret (Mustela putorius furo)”. Megan L. Cabot, et al. Journal of Exotic Pet Medicine. Volume 48, January 2024, Pages 1-5.

Source: https://www.sciencedirect.com/science/article/pii/S1557506323000721


Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Clinical outcomes and association with disease progression and survival of subclinical bacteriuria in cats with chronic kidney disease: a multicenter retrospective study.

Like0
Dislike1

Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases.

Like0
Dislike1

A Systematic Review and Meta-Analysis on the Global Seroprevalence of Porcine Reproductive and Respiratory Virus (PRRSV) in Pigs and Wild Boars: A Widespread and Impactful Swine Virus.

Like0
Dislike1

WSU seeks to curb deadly pneumonia threatening bighorn sheep recovery

Like0
Dislike1

Pet Insurance Market Could Exceed USD 113.7 Billion by 2035, as Rising Veterinary Costs and Expanding Insurance Penetration

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top